After SIL@T treatment, the proportion of mature DCs in cervical lymph nodes increased, effector T cells were activated in the spleen, and the infiltration of CD8+ T cells in brain metastases was improved, all of which supported the immune activation ability of SIL@T against brain metastases. This evidence concerns the gene CD8A and squamous cell intraepithelial neoplasia.